Flibanserin, “Female Viagra’’ A Molecule from Bench to Bed. FDA approved flibanserin in 2015, after being rejected twice, for the treatment of premenopausal women with generalized hypoactive sexual desire disorder (HSDD). F libanserin is a novel, non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of HSDD women. HSDD is characterized by reduced sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty and is not accounted for by coexisting conditions, use of medications, or relationship problems.
Flibanserin, has been reviewed three times by the FDA and discussed twice at public advisory committee meetings. The first advisory committee, convened in 2010, unanimously recommended against approval. In the two phase 3 trials, one primary end point, satisfying sexual events, was achieved, but the other, daily…
